 SAN DIEGO and TOKYO, May 12, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. Kyowa Kirin, TSE: 4151, a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced updated clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta PI3Kδ inhibitor in clinical development for the treatment of B-cell malignancies, in combination with zanubrutinib marketed as BRUKINSA, an inhibitor of Brutons tyrosine kinase developed by BeiGene, Ltd. 